“Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(2), p. s1. doi:10.25251/skin.6.supp.1.